Novo Nordisk, Canada
Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country authorised to assist in chronic weight management and to reduce the risk of non-fatal myocardial infarction (MI) in adults with a body mass index (BMI) of 27 kg/m² or greater, who have established cardiovascular disease.
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
Wall Street Journal on MSN1d
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionThe Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...
A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback